Introduction:
In the closely watched case of Dabur India Limited v. Patanjali Ayurved, the Delhi High Court has restrained Patanjali from broadcasting advertisements that disparage Dabur’s iconic Chyawanprash product. The interim order was issued by Justice Mini Pushkarna on July 3, 2025, after detailed arguments were heard on Dabur’s applications seeking urgent injunctions against Patanjali’s aggressive comparative advertising campaign. The dispute concerns allegations of false claims and malicious comparisons that allegedly misled consumers and tarnished Dabur’s reputation as India’s oldest and best-selling Chyawanprash manufacturer. The matter dates back to December last year, when Dabur filed a civil suit and sought an injunction against Patanjali’s marketing practices. However, according to Dabur, Patanjali escalated its campaign after summons were served, running 6,182 ads over a single week targeting Dabur’s product, and portraying it as “ordinary” compared to Patanjali’s version. The suit highlights critical issues of fair competition, consumer protection, and ethical advertising practices, especially in the fiercely competitive Ayurvedic and FMCG segments, where brands often rely on traditional formulations and consumer trust built over generations. The outcome of this case will likely set an important precedent for advertising standards in India’s herbal and ayurvedic product market.
Arguments of Both Sides:
Senior Advocate Sandeep Sethi, appearing for Dabur, presented detailed arguments asserting that Patanjali’s advertisements not only compared the two products unfairly but also misrepresented facts in ways that were likely to deceive the public. He argued that Patanjali claimed to use over 51 herbs in its Chyawanprash formulation, but the actual ingredients used numbered only 47, a discrepancy that made the advertising false and misleading. Sethi also contended that Patanjali’s advertisements suggested Dabur’s product, which uses 40 herbs as per traditional Chyawanprash formulations, was inferior and “ordinary,” implying that only Patanjali adhered to authentic ayurvedic texts. This, he said, amounted to clear disparagement rather than mere puffery or permissible comparative advertising. Sethi further submitted that Patanjali’s use of mercury, an ingredient alleged to be unfit for consumption by children, created unwarranted safety concerns around Dabur’s established product, damaging its reputation and consumer trust. Dabur’s counsel argued that these statements crossed the line into malicious falsehoods, designed to damage Dabur’s standing as a market leader and sway customers unfairly. On the other hand, Senior Advocate Jayant Mehta, appearing for Patanjali, robustly denied these allegations, asserting that Patanjali’s advertising was truthful, based on its own proprietary formulation which complies fully with traditional ayurvedic texts and government-prescribed standards. Mehta argued that the statements about the number of herbs were not intended as precise scientific claims but as general representations of the product’s richness and adherence to ayurvedic principles. He maintained that Patanjali’s references to Dabur’s formulation as “ordinary” fell within the permissible boundaries of competitive advertising, which allows businesses to highlight their strengths even if it indirectly points out perceived weaknesses in rival products. Mehta also emphasized that all ingredients in Patanjali’s Chyawanprash were approved for human consumption and met regulatory standards, including the use of bhasmas (purified metallic preparations) as recognized in classical ayurveda. He argued that the ads should be seen in the context of fair market practices, not as malicious attacks. Moreover, Patanjali’s counsel challenged Dabur’s claims on jurisdiction, arguing that since both parties are based in different states and the advertisements were aired nationwide, the Delhi High Court’s territorial jurisdiction could not be invoked based solely on Dabur’s assertions of harm.
Court’s Judgement:
After considering the rival arguments, Justice Mini Pushkarna ruled in favor of Dabur’s applications for interim injunctions, noting that the comparative advertisements run by Patanjali went beyond mere self-promotion and amounted to actionable disparagement. The Court observed that while comparative advertising is permitted under Indian law, it cannot extend to making false or misleading statements that demean a competitor’s product or misrepresent its quality. Justice Pushkarna found prima facie evidence that Patanjali’s advertisements crossed this line, especially in the repeated portrayal of Dabur’s Chyawanprash as “ordinary,” which, combined with unsubstantiated claims of ingredient superiority, created an overall impression of Dabur’s product being inferior or substandard. The Court emphasized that Dabur’s established market reputation built over decades and its iconic status as a pioneer in commercial Chyawanprash production made it particularly vulnerable to irreparable harm from such targeted advertising. The bench cited previous Supreme Court judgments like Reckitt & Colman of India Ltd. v. Kiwi TTK Ltd. and Pepsi Co. Inc. v. Hindustan Coca Cola Ltd., which laid down the test for disparagement: an ad may extol one’s own product but must not denigrate another’s. Applying this standard, the Court held that Patanjali’s campaign failed to maintain the distinction between permissible puffery and impermissible disparagement. The Court further noted the alarming volume of advertisements aired within a short span of one week—6,182 instances—suggesting a concerted effort to dominate public perception and cause maximum commercial harm to Dabur. The Court rejected Patanjali’s argument that general references to herb counts could not amount to misrepresentation, holding that when such specific numbers are repeatedly used in direct comparisons, they are capable of misleading average consumers into believing factual inaccuracies. On the question of mercury use, the Court observed that advertising content creating doubts about the safety of a competitor’s product without credible scientific proof was irresponsible and damaging, especially in a health product targeted at children and families. Accordingly, the Court restrained Patanjali from airing, publishing, or circulating advertisements that directly or indirectly disparage Dabur’s Chyawanprash or present misleading comparisons regarding the number or nature of herbs used. Justice Pushkarna’s bench concluded that Dabur had made a strong prima facie case for injunction, and balance of convenience lay in favor of protecting Dabur’s longstanding goodwill until the matter is fully adjudicated. The Court scheduled the next hearing before the roster bench on July 14, 2025, and clarified that detailed reasoning would follow in a reserved order. This interim relief reaffirms the judiciary’s commitment to maintaining fair competition standards while protecting iconic brands from deceptive trade practices.